The ICD-11 code 2A90.B represents the classification for Anaplastic large cell lymphoma, ALK-negative. This specific subtype of lymphoma is characterized by the absence of anaplastic lymphoma kinase (ALK) gene rearrangement, which distinguishes it from the ALK-positive variant. Anaplastic large cell lymphoma is a type of non-Hodgkin lymphoma that is primarily derived from T-cells and is known for its distinct morphological features.
Patients with ALK-negative anaplastic large cell lymphoma typically present with a variety of symptoms, including enlarged lymph nodes, fever, weight loss, night sweats, and fatigue. Diagnosis of this condition may involve a combination of physical exams, imaging tests, biopsies, and molecular testing to confirm the absence of the ALK gene rearrangement. Treatment options for ALK-negative anaplastic large cell lymphoma may include chemotherapy, radiation therapy, stem cell transplantation, or targeted therapy based on the individual’s specific characteristics and disease stage.
Table of Contents:
- #️⃣ Coding Considerations
- 🔎 Symptoms
- 🩺 Diagnosis
- 💊 Treatment & Recovery
- 🌎 Prevalence & Risk
- 😷 Prevention
- 🦠 Similar Diseases
#️⃣ Coding Considerations
The SNOMED CT code equivalent to ICD-11 code 2A90.B, which pertains to Anaplastic large cell lymphoma, ALK-negative, is 102447000. This code specifically identifies cases of this type of lymphoma that do not express the ALK protein, making it an essential tool for healthcare professionals to accurately document and track such diagnoses. SNOMED CT is a comprehensive clinical terminology system that enables consistent coding and classification of health-related information for data exchange, analysis, and decision support. By using standardized codes like 102447000, healthcare providers can improve communication, ensure interoperability of health records, and enhance the accuracy of clinical research and epidemiology studies. Utilizing specific codes helps streamline healthcare processes and facilitates effective patient care and management.
In the United States, ICD-11 is not yet in use. The U.S. is currently using ICD-10-CM (Clinical Modification), which has been adapted from the WHO’s ICD-10 to better suit the American healthcare system’s requirements for billing and clinical purposes. The Centers for Medicare and Medicaid Services (CMS) have not yet set a specific date for the transition to ICD-11.
The situation in Europe varies by country. Some European nations are considering the adoption of ICD-11 or are in various stages of planning and pilot studies. However, as with the U.S., full implementation may take several years due to similar requirements for system updates and training.
🔎 Symptoms
Symptoms of 2A90.B (Anaplastic large cell lymphoma, ALK-negative) can vary depending on the individual and the severity of the disease. Common symptoms include fatigue, weight loss, fever, night sweats, and unexplained itching. Patients may also experience swelling in the lymph nodes, typically in the neck, armpits, or groin.
Some individuals with 2A90.B may present with a visible lump or mass under the skin, which can be painful or tender to the touch. Skin lesions or ulcers may also develop in affected areas. Additionally, patients may experience shortness of breath, coughing, or chest pain if the lymphoma has spread to the lungs.
In more advanced cases, individuals with 2A90.B may experience symptoms related to organ compromise, such as abdominal pain, nausea, vomiting, or jaundice. Neurological symptoms, such as headaches, seizures, or confusion, may occur if the lymphoma has spread to the brain or spinal cord. It is important for individuals experiencing these symptoms to seek prompt medical attention for a thorough evaluation and diagnosis.
🩺 Diagnosis
Diagnosis methods for 2A90.B (Anaplastic large cell lymphoma, ALK-negative) typically involve a thorough physical examination by a healthcare provider to assess for any signs or symptoms of the condition. Patients may present with lymphadenopathy, fever, weight loss, and fatigue, which may prompt further investigation.
Laboratory tests such as complete blood count (CBC) and blood chemistry panels may be ordered to evaluate for abnormalities in blood cell counts or organ function that are commonly associated with lymphoma. Imaging studies such as CT scans, MRI, or PET scans may be used to visualize the extent of disease within the body and determine the presence of enlarged lymph nodes or masses.
A definitive diagnosis of Anaplastic large cell lymphoma (ALCL) is often confirmed through the examination of tissue samples obtained through a biopsy procedure. A pathologist will analyze the tissue under a microscope to identify the characteristic features of ALCL, including large and abnormal lymphoid cells. Immunohistochemistry and molecular testing may be used to further characterize the lymphoma cells and determine their ALK status.
Once a diagnosis of ALK-negative ALCL is confirmed, additional tests such as bone marrow biopsy, lumbar puncture, and flow cytometry may be performed to assess the extent of disease and determine the appropriate treatment approach. It is essential for healthcare providers to accurately diagnose ALCL to guide appropriate management and improve patient outcomes.
💊 Treatment & Recovery
Treatment for 2A90.B (Anaplastic large cell lymphoma, ALK-negative) typically involves a combination of chemotherapy and radiation therapy. Chemotherapy drugs such as cyclophosphamide, doxorubicin, vincristine, and prednisone are often used to target and kill cancer cells in the body. These drugs may be given orally or intravenously depending on the individual’s specific treatment plan.
In some cases, a stem cell transplant may be recommended for patients with 2A90.B. This procedure involves replacing damaged or diseased bone marrow with healthy stem cells to help the body produce new, healthy blood cells. Stem cell transplants are typically reserved for patients who have not responded well to other treatment options or who have experienced a relapse of the disease.
Targeted therapy is another treatment option for patients with 2A90.B. This approach involves using drugs that specifically target the cancer cells without harming healthy cells in the body. For ALK-negative cases of anaplastic large cell lymphoma, targeted therapy may include drugs that inhibit specific pathways or proteins that are involved in the growth and spread of cancer cells. These drugs may be used alone or in combination with other treatment modalities to improve outcomes for patients.
🌎 Prevalence & Risk
In the United States, the prevalence of 2A90.B (Anaplastic large cell lymphoma, ALK-negative) is estimated to be relatively low compared to other types of non-Hodgkin lymphomas. It accounts for approximately 3-5% of all cases of non-Hodgkin lymphoma in the US.
In Europe, the prevalence of 2A90.B is slightly higher than in the United States, with estimates suggesting that it accounts for approximately 5-7% of all cases of non-Hodgkin lymphoma in the region. The incidence of ALK-negative anaplastic large cell lymphoma shows some variation between different countries in Europe.
In Asia, the prevalence of 2A90.B is similar to that seen in Europe, with estimates suggesting that it accounts for approximately 5-7% of all cases of non-Hodgkin lymphoma in the region. The incidence of ALK-negative anaplastic large cell lymphoma in Asia also varies between different countries within the region.
In Africa, the prevalence of 2A90.B is relatively lower compared to other continents, with estimates suggesting that it accounts for approximately 2-4% of all cases of non-Hodgkin lymphoma in the region. The incidence of ALK-negative anaplastic large cell lymphoma in Africa also varies between different countries within the continent.
😷 Prevention
To prevent 2A90.B (Anaplastic large cell lymphoma, ALK-negative), it is important to understand the risk factors associated with this disease. One of the main risk factors for developing this type of lymphoma is exposure to certain chemicals or substances, such as pesticides and other toxic chemicals. It is important to take precautionary measures to limit exposure to these substances, either by avoiding direct contact or wearing protective equipment when handling them.
Another risk factor for developing 2A90.B is having a weakened immune system. Individuals with conditions that suppress the immune system, such as HIV/AIDS or undergoing organ transplantation, are at a higher risk for developing this type of lymphoma. To prevent 2A90.B in these cases, it is important to properly manage the underlying condition and follow a healthcare provider’s recommendations for maintaining a healthy immune system.
Genetic factors may also play a role in the development of 2A90.B, so individuals with a family history of cancer or certain genetic mutations may be at a higher risk. To prevent 2A90.B in these cases, genetic counseling and testing may be recommended to identify any potential risk factors and take appropriate preventive measures. Regular screening and monitoring for early signs of lymphoma can also help in preventing the progression of the disease.
🦠 Similar Diseases
One disease similar to 2A90.B is Anaplastic large cell lymphoma, ALK-positive (2A90.A). This subtype of ALCL is characterized by the presence of the anaplastic lymphoma kinase (ALK) gene rearrangement, which influences the prognosis and treatment approach. ALK-positive ALCL typically presents with similar clinical features as ALK-negative ALCL, such as lymphadenopathy, systemic symptoms, and extranodal involvement.
Another disease related to 2A90.B is Peripheral T-cell lymphoma, not otherwise specified (2A86). This category encompasses several different subtypes of T-cell lymphoma, including those that share similar histological and clinical features with ALCL. Peripheral T-cell lymphoma, NOS often presents with varying degrees of lymphadenopathy, B-symptoms, and extranodal involvement, making it important to differentiate from ALCL for appropriate management strategies.
One additional disease to consider in the differential diagnosis of 2A90.B is Hodgkin lymphoma, nodular lymphocyte predominant (2A40.C). This rare subtype of Hodgkin lymphoma shares some overlapping features with ALCL, such as nodal involvement, Reed-Sternberg cell variants, and CD30 expression. However, the distinct histological and genetic characteristics of nodular lymphocyte predominant Hodgkin lymphoma help differentiate it from ALCL and guide treatment decisions for affected patients.